Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review

Tessa Heestermans,1 Joyce L Browne,1 Susan C Aitken,2,3 Sigrid C Vervoort,4 Kerstin Klipstein-Grobusch1,5

ABSTRACT
Objective: The rapid scale up of antiretroviral treatment (ART) in sub-Saharan Africa (SSA) has resulted in an increased focus on patient adherence. Non-adherence can lead to drug-resistant HIV caused by failure to achieve maximal viral suppression. Optimal treatment requires the identification of patients at high risk of suboptimal adherence and targeted interventions. The aim of this review was to identify and summarise determinants of adherence to ART among HIV-positive adults.

Design: Systematic review of adherence to ART in SSA from January 2002 to October 2014.

Methods: A systematic search was performed in 6 databases (PubMed, Cochrane Library, EMBASE, Web of Science, Popline, Global Health Library) for qualitative and quantitative articles. Risk of bias was assessed. A meta-analysis was conducted for pooled estimates of effect size on adherence determinants.

Results: Of the 4052 articles screened, 146 were included for final analysis, reporting on determinants of 161 922 HIV patients with an average adherence score of 72.9%. Main determinants of non-adherence were use of alcohol, male gender, use of traditional/herbal medicine, dissatisfaction with healthcare facility and healthcare workers, depression, discrimination and stigmatisation, and poor social support. Promoters of adherence included counselling and education interventions, memory aids, and active disclosure among people living with HIV. Determinants of health status had conflicting influence on adherence.

Conclusions: The sociodemographic, psychosocial, health status, treatment-related and intervention-related determinants are interlinked and contribute to optimal adherence. Clinics providing ART in SSA should therefore design targeted interventions addressing these determinants to optimise health outcomes.

INTRODUCTION
Around 36.7 million people worldwide are currently living with HIV, of which 52% reside in sub-Saharan Africa (SSA).1 With the introduction of antiretroviral therapies (ARTs), HIV is increasingly becoming a chronic manageable disease.2 As a reflection of global roll-out efforts, the number of people living with HIV and receiving ART has increased by a third since 2013 and in 2015 about 17 million people received ART globally. Treatment success requires both a
sustainable supply of ART to clinics and lifelong adherence to treatment by patients. The importance of improving treatment adherence has resulted in a vast number of publications focussing on this topic.

Non-adherence is the most common reason for treatment failure, with potential risk to develop drug resistance through suboptimal viral suppression. Subsequent transmission of first-line ART-resistant HIV strains increases demand for second-line treatment often associated with poorer patient health outcomes and increasing healthcare costs. For these reasons, a thorough understanding of determinants of adherence to ART are paramount.

Studies on ART adherence showed that predictors and risk factors differ per region of the world, necessitating context-specific development of non-adherence profiles. This will enable healthcare providers to offer tailored care for patients at risk of non-adherence. The objective of this study was to identify and summarise determinants of adherence to ART among HIV-positive adults in SSA. For a comprehensive overview, both qualitative and quantitative studies were included, as qualitative studies may identify key themes not found, described or discussed in larger quantitative studies.

METHODS
Protocol and registration
The systematic review was conducted in accordance with the PRISMA guidelines and the Cochrane Handbook for Systematic reviews; the study protocol was registered in PROSPERO (ID: CRD42014014476).

Eligibility criteria, information sources and search strategy
A systematic literature search was performed in the following electronic bibliographic databases: PubMed/MEDLINE, The Cochrane Library, EMBASE, Web of Science, POPLINE, and the Global Health Library for all publications up to 27 October 2014. Search terms composed of MeSH and combined text for domain: ‘HIV positive adults receiving ART in SSA’, outcome ‘Patient Compliance’ and determinant ‘Risk factors’, ‘Determinants’ or ‘Predictors’. For the complete search strategy see online supplementary data 1. Filters were applied to exclude articles regarding infants, children and geographical locations other than SSA. All duplicates were removed using EndNote X7. No restriction based on year of publication, study design or language was applied. Given the comprehensive approach of the search, references were not checked, except those from a recent global systematic review, which did not yield additional articles.

Study selection
Titles and abstracts were independently screened for inclusion eligibility by two out of three reviewers (TH, JLB, SCA). Inclusion criteria were: study population of 15 years or older, living in SSA, HIV-positive, currently receiving ART, and available adherence information. Age cut-off was based on previous systematic reviews and WHO/UNICEF Health Indicator guideline. Studies reporting on non-SSA populations were only included if the abstract indicated data were presented stratified for SSA participants. Eligible studies could be qualitative and/or quantitative. Animal, biomedical studies, case reports, non-peer-reviewed published reports of proceedings, conference abstracts, secondary analyses, without main focus on the region of SSA and studies that are written in neither English nor Dutch were excluded. Discrepancies between reviewers in this process were discussed and resolved by full-text evaluation. In case of incomplete data or unavailable full-text articles, two attempts were made to contact the corresponding author via email; no reaction resulted in exclusion of the study. Post hoc, a random 10% of 332 articles excluded based on region was assessed if the article contained any results for SSA. This was not the case.

Data collection process and data items
Data extraction was performed using a standardised data extraction form. For each article, name of the first author, publication year, country and geographical region, that is, Central-Africa, East-Africa, Southern Africa and West-Africa following the index of National Library of Medicine—Medical Subject Headings, study design, aim of study, study setting, adherence outcome, sample size, treatment status (initiating or already on ART), adherence assessment method and determinants/risk factor outcome were retrieved. Determinants were coded according to themes: sociodemographic and socioeconomic, treatment and health facilities, psychological, health status, and counselling and education interventions. These themes were adjusted where necessary in the writing process to assure that all determinants fitted within the framework.

Data extraction was carried out by a single reviewer (TH), who was not blinded for journal and author details. If clarifications on data extraction were needed, one of the two reviewers was contacted (JLB, SCA). Ten per cent of the qualitative studies were randomly controlled for uniformity in data extraction by a second reviewer (SCV). If data from the same study were used in multiple articles, the article reporting on the largest sample size or data source was used. For longitudinal studies, adherence measurement of the first time point was used to facilitate comparability across studies and to reduce loss to follow-up bias.

Quality assessment and risk of bias in individual studies
Quantitative studies
For quality assessment of quantitative studies, an adapted version of the Cochrane Collaboration tool was applied as previously used in comparable reviews. Studies were scored according to the following criteria: blinding of researcher or clinicians, selection of study population, completeness and origin of data.
(measurements performed by authors or database research), clarity of outcome definition, and whether and how confounders were taken into account. Risk of bias was assigned as low, high or unclear risk, according to the quality assessment tool previously described.14

Qualitative studies
Qualitative articles were scored on their risk of bias using a previously developed approach by Vervoort et al20 focussing on (1) participants of the study: nature of sample, recruitment strategy, population, sample size; (2) data collections: validity measurements, quality of data collector, interview type, data triangulation, thickness of data; and (3) data analysis: coding procedure, interpretation, validity measurements and triangulation analysis. Bias risk was assigned as one of the following levels: satisfactory (S), dubious or not mentioned (D), and unsatisfactory (U). The nature of the sample was described as convenience (C) or purposive (P).

Mixed-method studies
Studies which combined qualitative and quantitative methods were scored by both risk of bias assessments listed above.

Summary measures, synthesis of results and risk of bias across studies
Meta-analysis was performed to obtain a summary measure based on pooled estimates on adherence determinants derived from the respective ORs, relative risks (RR) and corresponding 95% CI. If complete numbers of (non-)events were available, RRs were converted into ORs. If this was not possible, separate analyses for ORs and RRs were presented. Determinants reported in at least two studies were weighted based on the inverse of the variance as an estimate of statistical size. Owing to lack of reported risk estimates, not all studies included in this systematic review were suitable to be included. Statistical analyses were performed with RevMan V.5.3; (Review (RevMan) [Computer Program]. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration, 2014.) statistical significance was set at a two-sided p value of <0.05. Heterogeneity was measured using the I2 statistic.21 Possible publication bias was assessed visually through funnel plots per determinant.

Determinants were described narratively when based on qualitative data, or if pooling of results was not possible due to the nature of the data, using a mixed-methods approach. For mixed-methods studies, results were analysed as either quantitative or qualitative depending on reported outcome.

RESULTS
A total of 4052 articles were identified through the systematic literature search (see flow diagram in figure 1). After removing duplicates, 2353 articles were screened on title and abstract, 2046 articles did not meet inclusion criteria and were excluded. After full-text assessment of the remaining 307 articles, a total of 146 articles were included for the final analysis. Of these 146 articles reporting on determinants of (non-)adherence, 112 reported on quantitative and 37 qualitative data, with 3 studies using mixed methods.

Study characteristics of these articles are presented in table 1 and online supplementary data 2. Included studies were published between 2003 and 2014, and

---

**Figure 1** Flow diagram of the study selection for inclusion in the systematic review on determinants of adherence to ART in SSA. ART, antiretroviral treatment; SSA, sub-Saharan Africa.
Table 1  Overview of characteristics of studies on adherence of antiretroviral treatment (ART)

| Characteristics of studies on adherence | Group | N(%) |
|----------------------------------------|-------|------|
| Study type                              | Cohort| 44 (27) |
|                                        | Cross-sectional | 73 (45) |
|                                        | Qualitative | 37 (24) |
|                                        | Other | 7 (4) |
| Retrospective/ prospective             | Prospective | 136 (89) |
|                                        | Retrospective | 17 (11) |
| Region                                 | Central and East-Africa | 74 (45) |
|                                        | Southern Africa | 56 (35) |
|                                        | West-Africa | 36 (20) |
| Reported themes quantitative           | Sociodemographic | 75 (31) |
|                                        | Psychosocial | 40 (21) |
|                                        | Health status | 25 (14) |
|                                        | Treatment | 49 (22) |
|                                        | Intervention | 12 (10) |
|                                        | No significant determinants found | 8 (2) |

reported on 161,922 participants. Seventy-four articles reported on Central and East-Africa, 56 on Southern Africa and 36 on West-Africa. The average adherence rate was 52.5% (adherence 100%) and 72.9% (adherence 95%).

Bias assessment

Overall the performance of risk of bias was reasonably well, with only a few studies reporting high risk of bias on one or more of the categories (25% quantitative, 51.3% qualitative). Risk of bias assessment of the quantitative and qualitative studies is summarised in figure 2. Details for bias assessment for individual studies can be found in online supplementary files 3 and 4.

For quantitative studies, blinding of researchers and selection of study population was frequently unclear (69.6% and 49.1%). The other categories scored reasonably well, especially completeness of data and clear definitions of outcome (86.6% and 92.9%). For qualitative studies, validity of measurements in data collection and data analysis were least well defined (62.1%). Recruitment strategy was unclear in 56.8%. Other categories scored reasonably well.

The funnel plots, where possible, showed on visual inspection some evidence of publication bias in smaller studies considering younger age, that is, 15–35 years, low or no education, and discrimination (see online supplementary data 4).

Determinants of (non-)adherence

Sociodemographic, socioeconomic and lifestyle factors

Sociodemographic and socioeconomic determinants were reported in 105 studies.

Age was reported by 20 articles to be a determinant for adherence, with better adherence seen in older patients (>35 years) compared with younger patients.22–41

Eighteen studies reported gender influences on adherence. Eleven reported better adherence for women,31 42–51 but six reported the opposite.22, 28 41 52–54 Among men who had sex with men lower adherence was reported.55

Lower levels of education corresponded with non-adherence.42 45 52 53 56 57 and higher adherence was observed among patients with formal education.58–60 However, some articles reported the opposite.31 61–63

Alcohol use increased the risk of non-adherence.8 25 22 23 31 33 39 42 43 46 47 54 64 66 67 68 74 98 15 51

Suggested reasons were that patients may forget to take their medication as a consequence of alcohol use.55 Men may use alcohol to deny the reality of being HIV-positive.8 25

Religion was reported as both a barrier to and a promoter of adherence.33 67 71 74 79 82–85 88–102 Belief and faith that God provided the knowledge to make ART acts was observed to promote adherence,71 82 92 whereas studies reporting belief in religious cures for HIV over conventional medical approaches observed increased non-adherence.71 82 93

Employment showed conflicting outcomes; non-adherence was observed to be higher in unemployed44 61 64 98 and employed31 74 78 96 105 people. Similarly, both higher income and poverty were associated with non-adherence.33 28 42 47 49 51 52 55 59 85 87 96 104–107

Financial challenges, including transport costs, health facility costs and financial insecurity were associated with non-adherence.60 54 59 62 64 69 71 73 85 88 94 101 107–117

Food insecurity resulted in non-adherence through two mechanisms: stopping ART when food was unavailable to avoid aggravated (gastrointestinal) side effects, or because taking ART when insufficient food is available increased hunger.31 49 53 59 64 65 67 69 71 72 78 82 85 95 102 105 106 110 115 118–120

Other predictors reported to be associated with (non-)adherence were: distance to clinic,29 37 41 52 84 85 111 121 having children,24 58 96 117 123 geographical area,31 85 96 103 marital status,41 53 58 67 69 63 68 104 number of sexual partners,47 124 travelling,33 71 105 109 110 forgetting to take medication,39 71 83 84 hospital versus government ART initiative,31 living situation,87 tobacco use,47 unable to maintain healthy lifestyle,122 and language barriers.36

Treatment and health facilities

Seventy-five articles reported treatment determinants affecting adherence. The majority of these mentioned the negative influence of side effects on adherence, such as chronic diarrhoea and body shaping effects,
giving rise to the fear of involuntary disclosure of HIV status. The second most reported determinant was the influence of healthcare workers on patient adherence. A confidential and good relationship with healthcare providers resulted in better adherence. Non-adherence was seen when patients encountered unpleasant experiences with clinic staff, including rudeness, condemnation and fatigue.

Health facility determinants associated with non-adherence included experiencing no privacy at the facility, due to crowded pharmacies, consultations with multiple patients and lost files. Long waiting times and limited clinic hours were reported to lead to non-adherence, especially for employed people who would need to take time off to collect their medication.

Patients positive perceptions of ART, such as a strong belief in value of treatment and understanding importance of adherence, were associated with adherence, whereas rumours and false beliefs about ART, including that ART can cause harm and is a sexual stimulant, were associated with non-adherence.

Duration of treatment was observed to be associated with both adherence and non-adherence. Studies reporting better adherence over time suggested that long-term experience with ART results in better knowledge and strategies to incorporate ART use in daily life, social support, longer exposure to healthcare services, returning of strength and increased ability to manage side effects. Reasons for increased non-adherence could be the experience of no instant consequences for non-adherence and risk behaviour like smoking and use of alcohol. A proposed concept for adherence support interventions to reduce the consequences of duration of adherence was a shift towards promoting adherence as a means to live, rather than only survive. Other treatment and healthcare facility-related determinants were: pill burden as a predictor for non-adherence, change in medication or treatment, medication type, missing scheduled visits, pharmacy stock out, dietary instructions, study type and unclearly defined ART dosage.

Psychosocial
Seventy-three studies found psychosocial determinants affecting adherence. Disclosure, whereby people living with HIV hide or skip their medication to avoid disclosure of HIV status, was described most often in relation to non-
Fear of discrimination and/or experiencing stigma were determinants of non-adherence. This included being laughed at, exclusion from activities, being fired and alienation. Depression was found to be a predictor for non-adherence, and included reasons such as ‘ready to die’ and ‘loss of hope of ever getting better’.

Determinants associated with non-adherence were cognitive impairment, internalised stigma, psychological distress, trauma, masculinity, sharing medication, lack of commitment to therapy, isolation from family, caring for family, wanting to return to life before ART, being accused of infecting others, psychiatric care service and stress.

Health status

The most common health status-related determinant was perceived health status. Experiencing improved health on ART, increased confidence in medication, weight gain and being able to return to work were positively associated with adherence. Other determinants affecting both adherence and non-adherence were cognitive impairment, internalised stigma, knowledge of ART and/or HIV status of others, psychological distress, trauma, masculinity, sharing medication, lack of commitment to therapy, isolation from family, caring for family, wanting to return to life before ART, being accused of infecting others, psychiatric care service and stress.

Counselling and education interventions

Counselling and education were mentioned by 20 articles to be associated with adherence. Adherence training commonly consisted of strategies to cope with the medication and its side effects. Patients who had poor knowledge of basic HIV concepts due to no or low-quality counselling were at higher risk of non-adherence.

The use of memory aids like mobile phones, radio alarms, watches, reminders of children and pill boxes were observed to be associated with adherence. Having a treatment partner or clinic buddy was observed to be associated with adherence.

Receiving support by non-governmental organisation/government and adherence self-efficacy were also reported determinants of adherence.

A total of 14 studies found no significant determinants of adherence.

Meta-analysis

Meta-analysis could be performed for 25 determinants: 12 sociodemographic and socioeconomic factors, 5 psychosocial, 4 treatment-related and 2 health status and intervention-related determinants. Results are summarised in figure 3, sample sizes and number of studies included per determinant are presented in online supplementary data 5.

Sociodemographic and socioeconomic factors

Determinants associated with a protective effect on adherence were not drinking alcohol (OR=0.41; 95% CI 0.27 to 0.65; I²=38%), non-use of herbal/traditional medicine/treatment (OR=0.56; 95% CI 0.38 to 0.83),

Non-adherence was associated with the following determinants: use of alcohol (OR=1.78; 95% CI 1.51 to 2.09; I²=39%),

binge drinking (OR=2.25; 95% CI 1.92 to 2.65; I²=18%),

male gender (OR=1.73; 95% CI 1.34 to 2.23; I²=60%),

younger age (15–35 years; OR=1.61; 95% CI 1.25 to 2.06; I²=92%),

low or no education (OR=1.80; 95% CI 1.09 to 2.98; I²=81%),

low-quality counselling were at higher risk of non-adherence.

The use of memory aids like mobile phones, radio alarms, watches, reminders of children and pill boxes were observed to be associated with adherence.

Having a treatment partner or clinic buddy was observed to be associated with adherence.

Receiving support by non-governmental organisation/government and adherence self-efficacy were also reported determinants of adherence.

A total of 14 studies found no significant determinants of adherence.

Meta-analysis could be performed for 25 determinants: 12 sociodemographic and socioeconomic factors, 5 psychosocial, 4 treatment-related and 2 health status and intervention-related determinants. Results are summarised in figure 3, sample sizes and number of studies included per determinant are presented in online supplementary data 5.
Other determinants were not significantly related to adherence, for example, formal education, (un)employment, high income and marital status. However, female gender and older age (35 to 50+ years) showed trends in favouring adherence (OR=0.72; 95% CI 0.50 to 1.03; $I^2=79\%$) and (OR=0.74; 95% CI 0.49 to 1.11; $I^2=86\%$), respectively.

Psychosocial
Adherence was associated with good social support (OR=0.51; 95% CI 0.37 to 0.71; $I^2=0\%$). Determinants predictive for non-adherence were: non-disclosure to others (OR=3.46; 95% CI 2.04 to 5.89; $I^2=66\%$); depression (OR=2.54; 95% CI 1.65 to 3.91; $I^2=52\%$); and discrimination (OR=2.88; 95% CI 1.31 to 6.36; $I^2=73\%$). Psychological distress was not related to ART adherence.

Health status
Contrary to the narrative assessment, CD4 count was predictive for non-adherence in the meta-analysis: CD4 ≥200 cells/mm$^3$ (OR=1.26; 95% CI 1.09 to 1.46; $I^2=40\%$); CD4 ≤200 cells/mm$^3$ (OR=2.00; 95% CI 1.03 to 3.87; $I^2=30\%$) and CD4≤50 cells/mm$^3$ (OR=2.22; 95% CI 1.41 to 3.50).
Counselling and education interventions

Having no treatment partner was associated with increased likelihood of non-adherence (OR=7.24; 95% CI 1.73 to 30.3)\textsuperscript{156} conversely having a treatment partner (OR=0.57; 95% CI 0.51 to 0.64; I²=0%)\textsuperscript{12 23} was associated with increased adherence.

**DISCUSSION**

Our systematic review complements the existing body of literature, and identified numerous determinants influencing adherence to antiretroviral medication in SSA. Significant determinants for quantitative and qualitative studies of non-adherence were the use of alcohol, male gender, use of traditional/herbal medicine, dissatisfaction with healthcare facility and healthcare workers, depression, discrimination and stigmatisation, and poor social support. Promoters of adherence included counselling and education interventions, memory aids, and active disclosure among people with HIV. Determinants of health status had conflicting influence on adherence.

Langebeek et al\textsuperscript{11} performed a meta-analysis on predictors of adherence globally, and Mills et al\textsuperscript{15} compared developed and developing countries. A number of comparable determinants were found including substance abuse, concerns about ART or necessity of ART, satisfaction with the healthcare provider, depression, stigma, social support, financial constraints and pill burden.\textsuperscript{11}

Our approach focussed on determinants of adherence for people living with HIV in SSA, who constitute about two-third of HIV patients worldwide, and as such we were able to identify specific determinants relevant for this setting, including, for example, food insecurity, use of traditional herbs and medicine, and stigma. Trust and satisfaction with a healthcare provider may be more important in SSA countries with a low and medium Human Development Index,\textsuperscript{11} as well as issues of access to healthcare, impact of financial constraints, and disruption of services and medication distribution.\textsuperscript{11 12}

A strength of this systematic review is our mixed-methods approach, in which we combined a meta-analysis with a narrative review and included both quantitative and qualitative studies and the comprehensive search undertaken including databases that specifically focus on low-income and middle-income country-based research.

A number of limitations should be considered. Importantly, this systematic review and inference of results is limited by the quality of the individual papers underlying the process. For example, a high risk of bias was introduced with the limited consideration of confounders on the association between determinant and exposure. Likewise, if studies did not ask about determinants, this information was not captured in this review, a rather general limitation of studies. As the majority of data extractions were completed by one reviewer, this could have introduced bias; however, all questions related to inclusion/exclusion of a study were discussed with the investigator team.

We observed significant heterogeneity in measurements and definition of optimal adherence and inclusion criteria for participants in the different studies. Various methods were employed to assess adherence: self-report questionnaires, pill count, pharmacy refill, visual analogue scale, viral load, CD4 cell count, Center for Adherence Support Evaluation (CASE), Community Programs for Clinical Research on AIDS (CPCRA), electronic medication monitors and the AIDS clinical trial group adherence scale. Although some have been validated, no consensus exists about the extent of their validity or gold standard. Direct measurement of blood drug level concentration was not used in any of the studies. We considered the heterogeneity in the assessment of risk of bias by assessing all varieties and their appropriateness and applicability within the paper. For example, self-report has been validated for adherence assessment in rural areas, and therefore was considered a low risk of bias method in this review, even though the exact execution will determine its ultimate validation. Future studies should consider seeking consensus for the optimal tool to assess adherence, building on the available assessment of methods\textsuperscript{156–158} and considering practical limitations for application in SSA settings. For example, the 30-day analogue scale may be a promising approach for its convenient and reliable results.\textsuperscript{158–172}

**Clinical implications**

Our comprehensive overview of determinants that affect (non-)adherence could be of great use to optimise ART clinical service and adherence support within the current healthcare systems. Identified determinants allow for tailored support and interventions to be developed, evaluated and when effective, implemented in regions with scarce resources.

Interaction/clustering observed between determinants allow clinics to identify high-risk individuals most likely to benefit from targeted interventions. In fact, this is an active area of research and ample examples exist for specific evidence-based interventions.

For people living with HIV receiving ART who struggle with adherence as a result of the burden of monthly visits to crowded clinics, travel costs and/or time off work, a support group of several other persons receiving ART could be helpful whereby the group members take turns collecting medications.\textsuperscript{173 174}

For the strongest individual predictor of (non-)adherence, alcohol use, a number of interventions have been identified. These include brief health provider-initiated alcohol interventions for people living with HIV\textsuperscript{87 175} and the WHO-proposed intervention framework with brief consultations focused on alcohol reduction.\textsuperscript{176}

Interventions focused on younger patients include personalised, interactive and daily SMS reminders.\textsuperscript{177} Group-based counselling intervention for depression can potentially increase adherence.\textsuperscript{179} Other important interventions focus on improving quality of healthcare delivered in a system usually underfunded and overstretched. These include decentralisation of ART...
In conclusion, determinants of (non-)adherence in SSA identified in this review could facilitate the development, evaluation and implementation of targeted interventions. Given the increased accessibility of ART in SSA, optimising adherence will improve the health of millions of people living with HIV.

Author affiliations

1Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
2Ndlovu Research Consortium, Elandsdoorn, South Africa
3Division of Epidemiology & Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Acknowledgements

The authors would like to thank Professor Dr Rob Scholten for his advice on the meta-analysis conducted for the current study.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Global AIDS Update 2016. 2016. http://www.unaids.org/en/resources/documents/2016/Gl-oabal-AIDS-update-2016
2. Dorman D, Saag MS. Decline in lomactor functions over time in HIV-infected patients. AIDS 2014;28:1531–2.
3. VanyukondJera J, Mitchell K, Asimisw-Kateera B, et al. Antiretroviral drug adherence in Rwanza: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care 2013;25:1504–12.
4. Dahab M, Charalambous S, Karstaed AS, et al. Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health 2010;10:1-4.
5. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008;197 (Suppl 3):S272–8.
6. Mbuagbaw L, Thabane L, Ongolo-Zogo P, et al. Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial. AIDS Res Ther 2012;9:1–10.
7. Garang PG, Odai RA, Kalyango JN. Adherence to antiretroviral therapy in conflict areas: a study among patients receiving treatment from Lacor Hospital, Uganda. AIDS Patient Care STDS 2009;23:743–7.
8. Nakimuli-Mpungu E, Bass JK, Alexandre P, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav 2012;16:2101–18.
9. Were NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009;6:e11.
10. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679–90.
11. Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med 2014;12:142.
12. Mills E, Nachega J, Bangsberg D, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3:2039–64.
13. Meher D, Liretari A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PLoS Med 2009;6:1–2.
14. Higgins JP, Green S, Deeks JJ, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. 2008;187–325. http://reprints.wilseose.ac.uk/85834/
15. Thomson Reuters EndNote; EndNote Viewer X7.3.1 (Bld8614). 2014.
16. WHO. Global AIDS Response Progress Reporting 2016. Geneva, Switzerland, 2016.
17. U.S. National Library of Medicine. Medical Subject Headings. NIH. Global AIDS Response Progress Reporting 2016 (cited 25 February 2015). http://www.nlm.nih.gov.proxy.library.uu.nl/mesh/meshhome.html
18. Browne JL, Schrier VJ, Grobbee DE, et al. HIV, antiretroviral therapy and disorders in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2015;70:91–8.
19. Calvert C, Ronsmans C. HIV and the risk of direct obstetric complications: a systematic review and meta-analysis. PLoS ONE 2013;8:e74848.
20. Vervoort SC, Borliffs JC, Hoepelman AI, et al. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS 2007;21:271–81.
21. Deeks JJ. Chapter 9: Analysing data and undertaking. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011) 2011:1–43.
22. Alemu H, Haile Mariam D, Tsai AO, et al. Correlates of highly active antiretroviral therapy adherence among urban Ethiopian clients. Afr J AIDS Res 2011;10:263–70.
23. Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS ONE 2013;8:e53586.
24. Kunutsor S, Evans M, Thoulass J, et al. Ascertainment baseline levels of antiretroviral therapy adherence in Uganda: a multimethod approach. J Acquir Immune Defic Syndr 2010;55:221–4.
25. Memiah P, Sumba C, Elieene-Mesubi M, et al. The effect of depressive symptoms and CD4 count on adherence to highly active antiretroviral therapy in sub-Saharan Africa. J Int Assoc Provid AIDS Care 2014;13:346–52.
26. Muya AN, Getasanter PE, Hertzmark E, et al. Predictors of nonadherence to antiretroviral therapy among HIV-infected adults in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care 2015;14:163–71.
27. Newman J, Irondo-Freaza J, Hemingway-Foday J, et al. Older adults accessing HIV care and treatment and adherence in the IeDEA Central Africa Cohort. AIDS Res Treat 2012;2012:725713.
28. Rougemont M, Stoll BE, Elia N, et al. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther 2009;6:1–12.
29. Wakibi SN, Ng’ang’a ZW, Mbugua GG. Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Res Ther 2011;8:43.
30. Watt MH, Maman S, Golin CE, et al. Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care 2010;22:381–9.
31. Weiser SD, Palar K, Frongillo EA, et al. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Ugandans. AIDS Care 2012;24:115–20.
32. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on therapy for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009;38:746–56.
33. Dahab M, Charalambous S, Hamilton R, et al. “That is why I stopped the ART”: patients’ and providers’ perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health 2008;8:63.
34. Nachega JB, Hlatshwayo D, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndr 2009;51:65–71.
35. Nozaki I, Dube C, Kakimoto K, et al. Social factors affecting ART adherence in rural settings in Zambia. AIDS Care 2011;23:831–8.
36. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003;17:1369–75.

Heestermans T, et al. BMJ Glob Health 2016;1:e000125. doi:10.1136/bmjgh-2016-000125
37. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. *PLoS ONE* 2010;5:e10584.

38. Diabate S, Alain M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d’Ivoire. *AIDS* 2007;21:1799–803.

39. Falang KD, Akubaka P, Jimam NS. Patient factors impacting antiretroviral drug adherence in a Nigerian tertiary hospital. *J Pharmacoepidemiol* 2012;3:138–42.

40. Shaahu VN, Lawoyin TO, Sangwawo OA. Adherence to highly active antiretroviral therapy (HAAT) at a Federal Medical Centre. *Afr J Med Sci* 2008;37:29–36.

41. Uzochukwu BC, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized antiretroviral treatment in southeast Nigeria. *Health Policy Plan* 2009;24:189–96.

42. Marcellin F, Boyer S, Protopappouc E, et al. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116). *Trop Med Int Health* 2008;13:1470–6.

43. Negash T, Ehlers V. Personal factors influencing patients’ adherence to ART in Addis Ababa, Ethiopia. *J Assoc Nurses AIDS Care* 2013;24:530–8.

44. Maqudu T, North D, et al. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. *Afr J AIDS Res* 2010;9:117–24.

45. Ndia M, Nsuya P, Meyer H, et al. Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study. *Patient Prefer Adherence* 2013;7:891–6.

46. JH, D’souza E, et al. Adherence to antiretroviral therapy (ART) during the early months of treatment in rural Zambian childhood cancer patients. *BMC Public Health* 2013;13:396–406.

47. Ndiaye M, Nyasulu P, Nguyen H, et al. Field adherence to highly active antiretroviral therapy in Senegal using a comprehensive picture from the patient perspective. *BMJ Public Health* 2012;12:716.

48. Byers S, Clegg I, Bonono C-R, et al. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. *Soc Sci Med* 2011;72:1383–92.

49. Kekwaletswe C, Morojele N. Alcohol use, antiretroviral therapy adherence, and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus. *Patient Prefer Adherence* 2014;8:401–13.

50. Naidoo P, Pelzer K, Louw J, et al. Predictors of tuberculosis (TB) and antiretroviral (ARV) medication non-adherence in public primary care patients in South Africa: a cross-sectional study. *BMC Public Health* 2013;13:396–406.

51. Ndiaye M, Nsuya P, Meyer H, et al. Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study. *Patient Prefer Adherence* 2013;7:891–6.

52. Sasaki Y, Kakimoto K, Dube C, et al. Adherence to antiretroviral therapy (ART) during the early months of treatment in rural Zambian childhood cancer patients. *BMC Public Health* 2013;13:396–406.

53. Bastard M, Fall M, Laníèce I, et al. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. *J Acquir Immune Defic Syndr* 2011;57:55–61.

54. Nwachú C, Ehrhoar O, Ejele O, et al. Adherence to antiretroviral therapy among HIV-infected subjects in a resource-limited setting in the Niger Delta of Nigeria. *Afr J Health Sci* 2011;18:181–8.

55. Unge C, Södergård B, Marrone G, et al. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. *PLoS ONE* 2010;5:e13613.

56. Birbeck GI, Kvalsvik MP, Byers PA, et al. Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. *Am J Trop Med Hyg* 2011;85:782–9.

57. Alakija KS, Fadaye A, Ogumnmedede JA, et al. Factors influencing adherence to antiretroviral medication in Ilorin, Nigeria. *J Int Assoc Physicians AIDS Care* (Chic) 2010;9:191–5.

58. Graham SM, Mugo P, Gichuru E, et al. Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high-risk sexual behavior, including men who have sex with men, in coastal Kenya. *AIDS Behav* 2013;17:1255–65.

59. Müñene E, Ekweeen E, Association between patient engagement in HIV care and antiretroviral therapy medication adherence: cross-sectional evidence from a regional HIV care center in Kenya. *AIDS Care* 2015;27:378–86.

60. Erah P, Arufah A. Adherence of HIV/AIDS patients to antiretroviral therapy in a tertiary health facility in Benin City. *Afr J Pharm Pharmacol* 2008;2:145–52.

61. Pelzer K, Friend-du Preez N, Ramlagan S, et al. Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa. *BMC Public Health* 2010;10:1111.

62. Afolabi L, Ijaduola KT, Fatusi AO, et al. Determinants of adherence to antiretroviral drugs among people living with HIV/AIDS in Ille-Ijesa Zone of Osun State, Nigeria. *Afr J Prim Health Care Fam Med* 2009;1:6–11.
125. Matovu SN, La cour K, Hemmingson H. Narratives of Ugandan women adhering to HIV/AIDS medication. *Occup Ther Int* 2012;19:176–84.

126. Tessema B, Bladigqne F, Mulu A, et al. Magnitude and determinants of nonadherence and HIV clinical outcomes among people living with HIV/AIDS in Northwest Ethiopia. *AIDS Res Ther* 2010;7:1–8.

127. Van Griensven J, Zachariah R, Mubago J, et al. Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with stavudine, virologic failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda. *Trans R Soc Trop Med Hyg* 2010;104:751–7.

128. Bhengu BR, Ncama BP, McNerney PA, et al. Symptoms experienced by HIV-infected Individuals on antiretroviral therapy in KwaZulu-Natal, South Africa. *Afr Nurs Res* 2011;24:1–9.

129. Obirikorang C, Selleh PK, Adu D, et al. Predictors of adherence to antiretroviral therapy among HIV/AIDS patients in the Upper West Region of Ghana. *ISRN AIDS* 2013;2013:1–7.

130. Sow P, Toure K, Coume M, et al. Predictors of ART adherence among HIV infected individuals in Dakar, Senegal. *J Med Med Sci* 2012;3:212–16.

131. Nachega JB, Beaton DW, Arul DL, et al. Treatment support to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. *J Acquir Immune Defic Syndr* 2006;43(Suppl 1):S127–33.

132. Carlucci JG, Kamanga A, Sheneberger R, et al. Predictors of adherence to antiretroviral therapy in rural Malawi. *Trop Med Int Health* 2008;13:615–25.

133. Etard J-F, Lanèche I, Fal-MBK, et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. *Trop Med Int Health* 2007;12:1191–8.

134. Jones C, Crook R, Spence A. Antiretroviral Therapy in Zomba: do partners on ART enhance adherence? *J Int Assoc Provid AIDS Care* 2014;13:497–500.

135. van Oosterhout JJ, Bodasing N, Kurnwardja JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. *Trop Med Int Health* 2005;10:464–70.

136. Lanèche I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. *AIDS* 2003;17:S103–8.

137. Bajunirwe F, Katabira EJ, Tisch DJ, et al. Adherence and treatment response among HIV-1 infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. *J Int Assoc Physicians AIDS Care* 2009;8:139–47.

138. Olowookere S, Fatiregun AA, Akinremi JO, et al. Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. *J Infect Dev Ctries* 2008;2:369–72.

139. Birbeck GL, Chomba E, Kwasundu M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. *Am J Trop Med Hyg* 2009;80:369–74.

140. Amberbir A, Woldekimiel K, Getachew S, et al. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. *BMJ Public Health* 2008;1:1–9.

141. Thyu A, Bebech T, Alemseged F, et al. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of south Ethiopia. *AIDS Res Ther* 2010;7:1–10.

142. Whetten K, Shirley K, Pence B, et al. Trauma history and depression predict incomplete adherence to antiretroviral therapies in a low income country. *PLoS ONE* 2013;8:1–7.

143. Adewuya AO, Afobabi MO, Ola BA, et al. The effect of psychological distress on medication adherence in persons with HIV infection in Nigeria. *Psychosomatics* 2010;51:68–73.

144. Okoror TA, Falade GO, Olurinlana A, et al. Exploring the cultural context of HIV stigma on antiretroviral adherence among people living with HIV/AIDS in southwest Nigeria. *AIDS Patient Care STDS* 2013;27:55–64.

145. Omosanya OA, Adegoke OT, Agboola SM, et al. Effects of stigmatization/discrimination on antiretroviral therapy adherence among HIV-infected patients in a rural tertiary medical center in Nigeria. *J Int Assoc Provid AIDS Care* 2014;13:260–3.

146. Belenky NM, Cole SR, Pence BW, et al. Depressive symptoms, HIV medication adherence, and HIV clinical outcomes in Tanzania: a prospective, observational study. *PLoS ONE* 2014;9:1–5.

147. Wroe EB, Hedd-Gauthier BL, Franke MF, et al. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. *Int J STD AIDS* 2014;1:1–5.

148. Nel A, Kagge A. The relationship between depression, anxiety and medication adherence among patients receiving antiretroviral treatment in South Africa. *AIDS Care* 2013;25:948–55.

149. Olisah VO, Baiyewu O, Sheikh TL. Adherence to highly active antiretroviral therapy in depressed patients with HIV/AIDS attending a Nigerian university teaching hospital clinic. *Afr J Psychiatry* 2010;13:275–9.

150. Nakimuli-Mpungo E, Mutumba B, Othengo M, et al. Psychological distress and adherence to highly active anti-retroviral therapy (HAART) in Uganda: a pilot study. *Afr Health Sci* 2009;9(Suppl 1):2–7.

151. Brinkley-Rubinstein L, Chadwick C, Graci M. The connection between serious life events, anti-retroviral adherence, and mental health among HIV-positive individuals in the Western Cape, South Africa. *AIDS Care* 2013;25:1581–93.

152. Skovdal M, Campbell C, Nyamukapa C, et al. When masculinity interferes with women’s treatment of HIV infection: a qualitative study about adherence to antiretroviral therapy in Zimbabwe. *J Int AIDS Soc* 2011;14:29.

153. Abasa AM, Todd J, Ekoru K, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. *BMJ Health Serv Res* 2008;8:1–10.

154. Oyugi JH, Byakika-Tusiime J, Aballa S, et al. Predictors of adherence to antiretroviral therapy in HIV-infected adults in a resource-limited setting: a retrospective study in rural Uganda. *Int J Nurs Stud* 2010;47:1142–19.

155. Abah OI, Ojeh VB, Musa J, et al. Clinical utility of pharmacy-based adherence measurement in predicting virologic Outcomes in an Adult HIV-Infected Cohort in Jos, North Central Nigeria. *J Int Assoc Provid AIDS Care* 2014;1:7–18.

156. Ford N, Darder M, Spellman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. *PLoS ONE* 2010;5:1–4.

157. Kebede A, Wabe NT. Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South West Ethiopia. *N Am J Med Sci* 2012;4:67–71.

158. Mayanja B, Ekoru K, Namugenyi H, et al. Patient’s worries before starting antiretroviral therapy and their association with treatment adherence and outcomes: a prospective study in rural Uganda, 2004. *AIDS Res Hum Retroviruses* 2009;25:1675–83.

159. Mitiku H, Abdosh T, Teklemariam Z. Factors affecting adherence to antiretroviral treatment in Harari national regional state, eastern Ethiopia. *ISRN AIDS* 2013:1–7.

160. Ncama BP, McNemey PA, Bhengu BR, et al. Social support and medication adherence in HIV disease in KwaZulu-Natal, South Africa. *Int J Nurs Stud* 2008;45:1757–63.

161. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. *AIDS* 2007;21:965–71.

162. Urugu C, Södergård B, Ekström AM, et al. Challenges for scaling up ART in a resource-limited setting: a retrospective study in Kibera, Kenya. *J Acquir Immune Defic Syndr* 2009;50:397–402.

163. Tadesse WT, Mekonnen AB, Tesfaye WH, et al. Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. *BMCToxicol* 2014;15:32.

164. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients in the GEFES Study. *AIDS* 2003;17:1505–13.

165. Morisky DE, Ang A, Krousel-Wood MW. Reliability of a medication adherence measure in an outpatient setting. *Am J Med Sci* 2005;330:128–33.

166. Oyugi JH, Byakika-Tusiime J, Charlesbois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *J Acquir Immune Defic Syndr* 2004;36:1100–2.

167. Giorlando TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clin Trials* 2004;5:74–9.

168. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with
electronic data and virological treatment outcome. AIDS 2002;16:269–77.

171. Maneesriwongul WL, Tulathong S, Fennie KP, et al. Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S119–22.

172. Kelly JD, Hubenthal EA, Lurton G, et al. Multiple self-report measures of antiretroviral adherence correlated in Sierra Leone, but did they agree? Int J STD AIDS 2013;24:931–7.

173. Decroo T, Koole O, Remartinez D, et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health 2014;19:514–21.

174. Rasschaert F, Telfer B, Lessitala F, et al. A qualitative assessment of a community antiretroviral therapy group model in Tete, Mozambique. PLoS ONE 2014;9:e91544.

175. Peltzer K, Phaswana-mafuya N, Petros G. Hazardous alcohol use among persons living with human immunodeficiency virus infection in the Eastern Cape, South Africa. J Psychol Africa 2009;19:247–52.

176. WHO Brief Intervention Study Group. A cross-national trial of brief interventions with heavy drinkers. Am J Public Health 1996;86:948–55.

177. Dowshen N, Kuhns LM, Johnson A, et al. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res 2012;14:e51.

178. Petersen I, Hanass Hancock J, Bhana A, et al. A group-based counselling intervention for depression comorbid with HIV/AIDS using a task shifting approach in South Africa: a randomized controlled pilot study. J Affect Disord 2014;158:78–84.

179. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010;376:39–40.

180. Bemelmans M, Van Den Akker T, Ford N, et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health 2010;15:1413–20.